EH
CN
Home
Haisco
Group Profile
Subsidiary Profile
Production Base
Production Equipment
Production Capacity
Products
corporate Culture
Enterprise Philosophy
Employee Benefits
Employees
Enterprise Magazine
Contact Us
Product
Narcotic Analgesics
Endocrine System Drugs
Enteral Parenteral Nutrition Drugs
Neuropsychiatric Drugs
Cardiovascular Drugs
Tumor Related Drugs
Drugs For Digestive Liver Disease
Other
Innovative R&D
Innovative R&D
Pipeline
Platform
Investor
Stock Information
Investor Hotline
Contact Us
EH
CN
Haisco
Group Profile
Subsidiary Profile
Production Base
Production Equipment
Production Capacity
Products
corporate Culture
Enterprise Philosophy
Employee Benefits
Employees
Enterprise Magazine
Contact Us
Product
Narcotic Analgesics
Endocrine System Drugs
Enteral Parenteral Nutrition Drugs
Neuropsychiatric Drugs
Cardiovascular Drugs
Tumor Related Drugs
Drugs For Digestive Liver Disease
Other
Innovative R&D
Innovative R&D
Pipeline
Platform
Investor
Stock Information
Investor Hotline
Home
>
News and media
>
media coverage
海思科：今年有多款仿制药将获批
2019-05-28 11:26:17
证券时报e公司讯，海思科(002653)在今日举办的投资者交流活动上表示，今年公司的富马酸替诺福韦二吡呋酯片已获批，预计还有注射用醋酸卡泊芬净、复方氨基酸注射液（18AA-Ⅸ）、复方维生素注射液（13）、磺达肝癸钠注射液、盐酸普拉格雷片等等多款仿制药将获批。
来源：凤凰网
原文链接：
http://finance.ifeng.com/c/7mplUNXLype
返回列表
